Radiopharm TheranosticsASX:RAD -5.00% Market Cap is A$47.30 Mil as of Jun. 24, 2026. The stock has 5 warning signs investors should review. Among 1,430 Biotechnology companies, Radiopharm Theranostics ranks worse than 69.37% on this metric.
Radiopharm Theranostics's quarterly market cap
increased
from Jun. 2024 (A$17.49 Mil) to Dec. 2024 (A$52.82 Mil) but then
declined
from Dec. 2024 (A$52.82 Mil) to Jun. 2025 (A$52.03 Mil).
Radiopharm Theranostics's annual market cap
declined
from Jun. 2023 (A$35.63 Mil) to Jun. 2024 (A$17.49 Mil) but then
increased
from Jun. 2024 (A$17.49 Mil) to Jun. 2025 (A$52.03 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Radiopharm Theranostics's Enterprise Value for Today is A$16.26 Mil.
Radiopharm Theranostics (ASX:RAD) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Radiopharm Theranostics Market Cap Related Terms
Radiopharm Theranostics Market Cap Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:RAD vs VRTX, REGN, ALNY: Market Cap Comparison
For the Biotechnology subindustry, Radiopharm Theranostics's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Radiopharm Theranostics Market Cap vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Radiopharm Theranostics's Market Cap distribution charts can be found below:
* The bar in red indicates where Radiopharm Theranostics's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Radiopharm Theranostics's Market Cap for the fiscal year that ended in Jun. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Radiopharm Theranostics (ASX:RAD) has a Market Cap of A$47.30 Mil as of Jun. 24, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Radiopharm Theranostics and its competitors. According to the industry distribution chart, Radiopharm Theranostics ranks #992 out of 1430 companies in the Biotechnology industry, placing it in the top 69.4%.
Is Radiopharm Theranostics' Market Cap too high?
Radiopharm Theranostics' current Market Cap is A$47.30 Mil. Based on the distribution chart, Radiopharm Theranostics ranks #992 out of 1430 companies in the Biotechnology industry, which is below the industry midpoint.
How does Radiopharm Theranostics' Market Cap compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Radiopharm Theranostics ranks #992 out of 1430 companies for Market Cap. This places Radiopharm Theranostics in the lower half of its industry. The industry median Market Cap is 117.26. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Biotechnology company?
The median Market Cap among Biotechnology companies is 117.26, based on 1,430 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Radiopharm Theranostics and its competitors. For the Biotechnology industry, the median Market Cap is 117.26 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Radiopharm Theranostics's current Market Cap is A$47.30 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Radiopharm Theranostics stock overvalued right now?
Radiopharm Theranostics (ASX:RAD) has a current Market Cap of A$47.30 Mil. The current Market Cap is A$47.30 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Radiopharm Theranostics (ASX:RAD), the current Market Cap is A$47.30 Mil as of Jun. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Radiopharm Theranostics Ltd is an Australian-based clinical-stage radiotherapeutics company targeting cancer. The company has a pipeline of approximately four licensed platform technologies, with diagnostic and therapeutic applications at both the pre-clinical and clinical stages of development. The company is engaged in research, development, and commercialization of health technologies.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:RAD has been successfully added to your